srakaoffer.blogg.se - Mhb cb to 1blocker

#Mhb cb to 1blocker trial#
#Mhb cb to 1blocker series#

Ankill J, Aure MR, Bjørklund S, Langberg S, Oslo Breast Cancer Consortium (OSBREAC), Kristensen VN, Vitelli V, Tekpli X, Fleischer T (2022) Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer NAR Cancer, 4 (1), zcac008 DOI 10.1093/narcan/zcac008, PubMed 35350772.

Amdal CD, Taylor K, Kuliś D, Falk RS, Bottomley A, Arraras JI, Barte JH, Darlington AS, Hofsø K, Holzner B, Jørgensen NMH, Mariano MP, Pe M, Piccinin C, Riccetti N, Schranz M, Wheelwright S, Bjordal K (2022) Health-related quality of life in patients with COVID-19 international development of a patient-reported outcome measure J Patient Rep Outcomes, 6 (1), 26 DOI 10.1186/s41684-1, PubMed 35348945.

#Mhb cb to 1blocker series#

Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022) ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series JCO Precis Oncol, 6, e2200015 DOI 10.1200/PO.22.00015, PubMed 35476549.Ali M, Fulci G, Grigalavicius M, Pulli B, Li A, Wojtkiewicz GR, Wang C, Hsieh KL, Linnoila JJ, Theodossiou TA, Chen JW (2022) Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy Neoplasia, 26, 100779 DOI 10.1016/j.neo.2022.100779, PubMed 35247801.Alaña L, Nunes-Xavier CE, Zaldumbide L, Martin-Guerrero I, Mosteiro L, Alba-Pavón P, Villate O, García-Obregón S, González-García H, Herraiz R, Astigarraga I, Pulido R, García-Ariza M (2022) Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma Cancers (Basel), 14 (2) DOI 10.3390/cancers14020421, PubMed 35053583.Aittokallio T (2022) What are the current challenges for machine learning in drug discovery and repurposing? Expert Opin Drug Discov, 17 (5), 423-425 DOI 10.1080/17460441.2022.2050694, PubMed 35255749.

(2022) Common variants in breast cancer risk loci predispose to distinct tumor subtypes Breast Cancer Res, 24 (1), 2 DOI 10.1186/s13054-x, PubMed 34983606 Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Augustinsson A, Baten A, Becher H, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H et al.

#Mhb cb to 1blocker trial#

(2022) Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial Radiother Oncol, 172, 1-9 DOI 10.1016/j.radonc.2022.04.020, PubMed 35476942 Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L et al.Publications published since 2000 from OUS - Division of Cancer MedicineĨ882 publications found (only first 1000 shown)